Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy.
![](/Public/En/images/g3_img02.png)
![](/Public/En/images/g3_img01.png)
HuidaGene Therapeutics to Attend 2024 BIO International Convention in California for Actively Expanding Global Collaboration
Shanghai and CLINTON (NJ), May 31th, 2024 – HuidaGene Therapeutics (“HuidaGene”), a global clinical-stage biotechnology company developing potentially curative genomic medicines, today announced that it will attend the 2024 BIO International Convention to be held from June 3 to 6, 2024 at the San Diego Convention Center in California, USA.
Dr. Alvin Luk, Co-founder and CEO of HuidaGene, and Ms. Xixi Zhu, Senior Director of Business Development of HuidaGene will attend the convention to showcase HuidaGene’s cutting-edge gene-editing technology and innovative gene therapy product pipeline, actively explore global collaboration, and further expand its global footprint. HuidaGene looks forward to conducting in-depth exchanges with multinational corporations and biotechnology companies from around the world on site, and exploring new opportunities for international cooperation and development.
The BIO International Convention, founded in 1993, is the largest, most professional, and influential biotechnology industry event in the world. It brings together leading biopharmaceutical companies, investors, and partners from around the world. Many collaborative activities are held during the conference, providing a platform for promotion and display for enterprises, technology parks, and research and development institutions in various countries. The conference is hosted by the Biotechnology Innovation Organization (BIO) in the United States. BIO is the world's largest biotechnology industry association representing biotechnology companies, academic institutions, and related institutions.
About HuidaGene
HuidaGene Therapeutics utilizes its proprietary CRISPR-based HG-PRECISE® platform to discover, engineer, and develop potentially curative genomic medicine. The Company is advancing clinical programs of HG004 in RPE65-associated inherited retinal disease (granted both ODD and RPDD), HG202 CRISPR RNA-editing in neovascular age-related macular degeneration, and the preclinical pipeline, including HG204 CRISPR RNA-editing in neurodevelopmental disease of MECP2 duplication syndrome (granted both ODD and RPDD by U.S. FDA and ODD by EMA), HG302 CRISPR DNA-editing for Duchenne muscular dystrophy (granted both ODD and RPDD), and HG303 CRISPR DNA-editing for Amyotrophic Lateral Sclerosis (ALS). The Company’s extensive intellectual property portfolio positions it as a leader in unleashing the full potential of genome medicine. Learn more at huidagene.com or on LinkedIn.
recommendations
-
Sep 06,2023
HuidaGene Therapeutics Announces First Patient Dosed Of The World's First Novel CRISPR/Cas13 RNA-Editing Therapy HG202 For Neovascular Age-related Macular Degeneration
-
Dec 19,2023
HuidaGene Announces Rare Pediatric Drug Designation Granted to HG302, A Novel CRISPR DNA-editing Therapy, for the Treatment of Duchenne Muscular Dystrophy
-
Aug 04,2023
HuidaGene and Kactus Announce Strategic Collaboration and License Agreement to Promote Commercialization of Next-Generation Gene Editing Enzyme, hfCas12Max®
-
Aug 07,2023
HuidaGene Therapeutics Receives FDA Rare Pediatric Disease Designation for HG004 to Treat Inherited Blindness